ABP-450 (prabotulinumtoxinA)
Episodic Migraine
Key Facts
About AEON Biopharma
AEON Biopharma is dedicated to broadening access to therapeutic botulinum toxin treatments, which are clinically proven but often constrained by cost and limited competition. Its lead candidate, ABP-450, is being developed as a full-label biosimilar to BOTOX®, with a pipeline targeting episodic and chronic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder. The company employs a strategic focus on the therapeutic market, aiming to create economic value for payers and healthcare systems while improving patient care through its patented injection techniques and rigorous biosimilarity program.
View full company profileAbout AEON Biopharma
AEON Biopharma is dedicated to broadening access to therapeutic botulinum toxin treatments, which are clinically proven but often constrained by cost and limited competition. Its lead candidate, ABP-450, is being developed as a full-label biosimilar to BOTOX®, with a pipeline targeting episodic and chronic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder. The company employs a strategic focus on the therapeutic market, aiming to create economic value for payers and healthcare systems while improving patient care through its patented injection techniques and rigorous biosimilarity program.
View full company profileAbout AEON Biopharma
AEON Biopharma is dedicated to broadening access to therapeutic botulinum toxin treatments, which are clinically proven but often constrained by cost and limited competition. Its lead candidate, ABP-450, is being developed as a full-label biosimilar to BOTOX®, with a pipeline targeting episodic and chronic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder. The company employs a strategic focus on the therapeutic market, aiming to create economic value for payers and healthcare systems while improving patient care through its patented injection techniques and rigorous biosimilarity program.
View full company profileAbout AEON Biopharma
AEON Biopharma is dedicated to broadening access to therapeutic botulinum toxin treatments, which are clinically proven but often constrained by cost and limited competition. Its lead candidate, ABP-450, is being developed as a full-label biosimilar to BOTOX®, with a pipeline targeting episodic and chronic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder. The company employs a strategic focus on the therapeutic market, aiming to create economic value for payers and healthcare systems while improving patient care through its patented injection techniques and rigorous biosimilarity program.
View full company profileAbout AEON Biopharma
AEON Biopharma is dedicated to broadening access to therapeutic botulinum toxin treatments, which are clinically proven but often constrained by cost and limited competition. Its lead candidate, ABP-450, is being developed as a full-label biosimilar to BOTOX®, with a pipeline targeting episodic and chronic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder. The company employs a strategic focus on the therapeutic market, aiming to create economic value for payers and healthcare systems while improving patient care through its patented injection techniques and rigorous biosimilarity program.
View full company profileTherapeutic Areas
Other Episodic Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| CT-132 | Click Therapeutics | Phase 3 |